Bioarray Genetics Presents at the 40th Annual San Antonio Breast…
This is a pivotal step toward eliminating the trial and error approach from breast cancer patients treatment.
FARMINGTON, Conn. (PRWEB)
December 05, 2017
Bioarray Genetics, Inc. (“Bioarray” or the “Company”) announced today that the Company will be presenting a pivotal study at the upcoming 40th Annual San Antonio Breast Cancer Symposium on December 7th.
Bioarray conducted a 582-patient clinical validation study that confirms the company’s lead test’s ability to identify a subset of triple negative breast cancer patients with resistant disease and the poorest prognosis. The research results will be presented in a poster, titled “A Predictive Test for Neoadjuvant Chemotherapy in Breast Cancer.”
The RNA-based test is administered at the time of diagnosis and provides clinicians with actionable information about the sub-group of triple negative breast cancer patients that are particularly difficult to treat and are characterized by having the poorest survival rates. This critical information, provided at the time of diagnosis, can impact treatment decisions at the front-end of the treatment plan to improve patient quality of life and outcomes. Currently there is a gap to provide this critical information to triple negative patients who are resistant to standard treatment, leaving clinicians to treat these patients on a trial and error basis, resulting in delayed time to appropriate and effective treatment. Patients and payors alike will benefit from the information afforded by the test with the potential for enhanced outcomes and the containment of costs.
Breast cancer ranks as the second leading cause of death among women with cancer in the United States, and triple negative breast cancer accounts for approximately 20 percent of the patients diagnosed each year. Identifying patient response to a form of therapy at the beginning of the treatment decision-making process can have considerable impact on patient outcomes and health economics.
Marcia Fournier, the CEO and Founder of Bioarray states, “This is a pivotal step toward eliminating the trial and error approach from breast cancer patients treatment. Reducing toxicity and improving outcomes is the by-product of advanced molecular diagnostic tests. Bioarray is delighted to be at the forefront of that change with the first predictive test for triple negative breast cancer patients.”
Bioarray plans to commercialize its lead test in 2018.
About Bioarray Genetics
Bioarray Genetics, Inc., a molecular diagnostics company, is focused on the development of predictive test that provide actionable information to clinicians in the treatment planning process for cancer patients to eliminate the trial and error approach to treatment. The company’s gene profiling platform serves as the foundation for the development of predictive tests that can be used for treatment planning, companion diagnostics, and drug research and development. The company’s pipeline of tests includes a predictive test for metastatic breast and colon cancers. Bioarray is a privately held company based in Farmington, CT. For more information on Bioarray, please visit http://www.bioarray.us.
Share article on social media or email: